KT Signs Business Agreement with NeuroSigma Following U.S. Approval of First ADHD Electronic Medicine

KT Collaborates with NeuroSigma on Domestic and International Commercialization and Joint Development of ADHD Electronic Medicine
Expanding to Digital Therapeutics Services for Neuropsychiatric Disorders Including Depression and Epilepsy
Promoting Domestic Commercialization and Production Base Establishment Linked with KT Digital Healthcare Platform

[Asia Economy Reporter Eunmo Koo] KT is partnering with NeuroSigma, a U.S. electronic medicine development company that was the first to receive approval from the U.S. Food and Drug Administration (FDA) for electronic medicine treating neuropsychiatric disorders, to advance electronic medicine business domestically and internationally.

On the 14th, KT announced that it signed a business agreement with NeuroSigma to collaborate on product development and commercialization in the field of electronic medicine treating neuropsychiatric disorders such as Attention Deficit Hyperactivity Disorder (ADHD), depression, and epilepsy.

NeuroSigma’s developed ‘Monarch eTNS (Monarch external Trigeminal Nerve Stimulation System)’ is a technology that treats neuropsychiatric disorders by stimulating brain nerves through an electronic patch rather than drugs, and it was the first electronic medicine for ADHD to receive FDA medical device approval. Using this technology, they plan clinical trials to expand indications to depression and epilepsy and obtain additional FDA approvals.

Leveraging this partnership with NeuroSigma, KT will promote support for the design and development of next-generation versions of the eTNS product based on artificial intelligence (AI), big data, and cloud capabilities, enhance monitoring and AI analysis services linked with the KT digital healthcare platform, and collaborate on domestic commercialization and establishment of domestic production bases.

Existing ADHD treatment drugs are central nervous system stimulants that may cause side effects such as headaches, anxiety, and addiction. In contrast, eTNS electronic medicine has milder side effects compared to drugs and has proven safety and efficacy, so KT expects high demand from patients and caregivers seeking alternatives to existing neuropsychiatric treatment drugs.

At the end of last year, KT established the ‘Digital & Biohealth P-TF’ under the CEO’s Future Value Promotion Office, and this year, Kim Hyung-wook, head of the Future Value Promotion Office, was inaugurated as president of the Digital Health Industry Association, showing strong commitment to fostering new businesses in the healthcare sector. KT is expanding its presence in the healthcare ecosystem by forming broad partnerships with hospitals, pharmaceutical companies, academic societies, and bio ventures.

Kim Hyung-wook, Vice President and head of KT’s Future Value Promotion Office, said, “Although digital therapeutics are still in the early stages domestically, their utility and growth potential are outstanding. Starting with business cooperation with NeuroSigma, we will actively nurture electronic medicine and digital therapeutics as new healthcare businesses and strive to expand the market.”

Leon Akchian, CEO of NeuroSigma, said, “KT’s digital healthcare platform will perfectly complement our eTNS product, which represents the convergence of medical and electronic engineering fields. Based on KT’s ICT capabilities, we will create additional value in design, functionality, and customer experience to advance our next-generation products.”

This content was produced with the assistance of AI translation services.